Callio Therapeutics is developing next-generation, dual-payload antibody-drug conjugates (ADCs) that enable targeted delivery of drug combinations to tumor cells, aiming to maximize therapeutic benefits for cancer patients
Callio Therapeutics is developing next-generation, dual-payload antibody-drug conjugates (ADCs) that enable targeted delivery of drug combinations to tumor cells, aiming to maximize therapeutic benefits for cancer patients.